Table 1.
Demographic and clinical characteristics of patients with diffuse large B‐cell lymphoma (DLBCL) treated with R‐CHOP (n = 120)
| Characteristic at diagnosis | No. of patients (%) |
|---|---|
| Age, median (range, years) | 59.5 (25–83) |
| Male gender | 75 (62.5%) |
| Performance status ≥2 | 10 (8.3%) |
| Histologic subtype | |
| DLBCL, NOS | 113 (94.2%) |
| T‐cell/histiocyte‐rich DLBCL | 6 (5.0%) |
| EBV‐positive DLBCL of the elderly | 1 (0.8%) |
| Ann Arbor stage | |
| I | 17 (14.2%) |
| II | 44 (36.7%) |
| III | 16 (13.3%) |
| IV | 43 (35.8%) |
| LDH ≥250 U/L | 55 (45.8%) |
| B symptoms present | 19 (15.8%) |
| Extranodal site involvement ≥2 | 35 (29.2%) |
| International prognostic index ≥3 (high risk) | 39 (32.5%) |
| GCB type | 50 (41.7%) |
| Primary treatment | |
| R‐CHOP + radiotherapy | 17 (14.2%) |
| R‐CHOP | 103 (85.8%) |
EBV, Epstein–Barr virus; GCB, germinal center B‐cell‐like; LDH, lactate dehydrogenase; NOS, not otherwise specified; R‐CHOP, rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone cyclophosphamide.